Targeting Cancer and Autoimmune Conditions with Donor-Derived EBV T Cells
Pascal Touchon, president and CEO of Atara Biotherapeutics, discusses the role of the Epstein-Barr virus in certain cancers and autoimmune conditions, the company’s platform technology for allogenic CAR T therapies, and why it has implications beyond EBV-driven diseases.